ClinicalTrials.gg
RecruitingNCT05821478ABCESS2Updated Jul 9, 2025

Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients

A Phase 3 interventional study of ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy and Lymecyclin and corresponding placebos of the experimental arm in Hidradenitis Suppurativa, sponsored by Institut Pasteur. Recruiting at 4 sites in France. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Institut Pasteur · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 53 studies in Hidradenitis Suppurativa with a site in France — 15 open to participants now, 25 under way, 10 of them phase 3. Hidradenitis Suppurativa · France.

Planned enrollment
34th of 45
92 · median 214
Started
2025
with 11 others
Phase 3
20 of 53
4 open now
Primary completion
2027-02
later than 9 of 24 live
Registered
11th of 53
by date

Among the 53 studies in Hidradenitis Suppurativa with a site in France, this one is the 34th largest by planned enrollment of the 45 interventional ones that give a count, is one of 12 that started in 2025, is one of 20 in phase 3, reaches primary completion later than 9 of the 24 other live ones, and was the 11th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

15 of the 53 studies in Hidradenitis Suppurativa with a site in France are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 62 Hidradenitis Suppurativa studies recruiting now, 34 (55%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Hidradenitis Suppurativa with a site in France, or all of them as a file.
02

Study summary

The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative

Read the detailed description

The antibiotic strategy is targeted against specific pathobionts which have been identified in HS lesions by the investigator's team.

Half of participants will receive a 3-week course of ceftriaxone + metronidazole treatment followed by 3 weeks of rifampicin + moxifloxacin + metronidazole combination, then 6 weeks of rifampin + moxifloxacin (experimental groupe), versus a 12 weeks course of lymecycline (control group) Double blind treatment phase will stop at week 12. All patients whatever their randomization arm or their remission status will begin follow-up treatment according to standard care recommendations (Société Française de Dermatologie): lymecycline, doxycycline or cotrimoxazole. Prescription will be upon decision of the investigator.

This maintenance treatment is not experimental.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • Antibioresistance
  • Antibiotherapy
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults \< 60 years old
  • Diagnosis of HS according to European Dermatology guidelines:

    • Recurrent inflammation occurring more than 2 times in the past 6 months in the inverse regions of the body, presenting with nodules, sinus-tracts and/or scarring.
    • Signs: Involvement of axilla, genitofemoral area, perineum, gluteal area (and infra-mammary areafor women). Presence of nodules (inflamed or noninflamed), sinus tracts (inflamed or noninflamed), abscesses, scarring (atrophic, mesh-like, red, hypertrophic or linear)
  • Active HS with i) ≥ 1 year of evolution and ii) ≥ 4 flares during the previous year
  • Clinical severity of HS at inclusion: Hurley stage 2
  • \< 35
  • Written from patient
  • Patient able to complete DLQI
  • Patients affiliated to the French health system (Assurance Maladie), except French state medical aid beneficiaries (Aide Médicale d'Etat)
  • Active compatible for men and women of childbearing or inability to procreate
  • Available laboratory blood test performed within the last 2-months

Non inclusion Criteria:

  • Person \< 18 and ≥ 60 years old
  • Former stage 3 HS
  • Previous use of the experimental treatment
  • Unauthorized drugs for the study during the month preceding the inclusion
  • Any to study treatments or (e.g. lactose, cornstarch, riboflavin notably):

pregnancy, breastfeeding, known allergy to experimental or reference drugs, wheat allergy, tendinopathy, , bradycardia, heart failure, heart rhythm disturbances, hydroelectrolytic disorders, hypokalemia, coagulation disorders, severe liver/kidney dysfunction, porphyria, mandatory use of nonsteroidal anti-inflammatory drugs (NSAIDs) for other medical conditions

  • Unbalanced diabetes (ie above 7%)
  • Dysphagia, untreated gastro-oesophageal reflux/ulcer
  • BMI ≥ 35
  • Immune suppression, inflammatory disease, including gastroenterologic and rheumatologic inflammatory conditions
  • Lactase deficiency, lactose and galactose intolerance
  • Malabsorption syndrome
  • Person living in the same household as another patient
  • Person under guardianship or curatorship
  • Individuals with any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g patient unable to complete DLQI, or poor predictable observance
  • Participation in another interventional research on health products studies
  • Patients requiring repeated (more than 3/year) use of antibiotics for a chronic disease other than HS
  • Alcohol-dependant patients defined as an addiction to alcohol with a negative impact on health, social or personal life

Exclusion criteria

Exclusion criteria:

Pregnancy Abnormal result of routine lab tests corresponding to to study treatments Unauthorized drug for the study during all the study (from study treatments interactions listed in the SmPC, Cf. unauthorized drug listed in non-inclusion criteria).

Development of to any of the study products and/or (e.g. lactose, corn starch, riboflavin).

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Experimental treatment

    a 3-week course of ceftriaxone (Rocephin) IV injection (daily dose 2g/day) \+ oral metronidazole (daily dose 1500mg) followed by a 3-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg) + metronidazole (daily dose 1500mg) followed by a 6-week course of oral rifampicin (Rifadin with 10mg/kg/day) + moxifloxacin (Izilox daily dose 400mg). A placebo for lymecycline will also be administered during this intensive treatment phase

    Drug: ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy

  • Active comparator
    Control

    12-week course of oral lymecycline (Tetralysal daily dose 452mg) Placebos for all experimental drugs will also be administered during this intensive treatment phase

    Drug: Lymecyclin and corresponding placebos of the experimental arm

Interventions

  • DrugROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy

    a 3-week course of ceftriaxone injection + oral metronidazole followed by a 3-week course of oral rifampicin + moxifloxacin +metronidazole followed by a 6-week course of oral rifampicin + moxifloxacin

    Also known as: Experimental treatment

  • DrugLymecyclin and corresponding placebos of the experimental arm

    12-week course of oral lymecycline.

    Also known as: Control treatment

06

What researchers measure

Primary outcomes

  1. Percentage of patients reaching clinical remission at week 12, defined by an improvement of 90% of the IHS4 score from the baseline (IHS4 (1))

    The clinical remission is defined as a 90% improvement of the International Hidradenitis Suppurativa Severity Score (IHS4) at week 12 compared to the baseline. The IHS4 score is a validated composite score developped to assess dynamically HS severity (1). It is calculated by adding the number of inflammatory nodules to the number of abscesses multiplied by 2 and to the number of draining tunnels multiplied by 4. A total score of 3 or less corresponds to mild severity HS, 4-10 to moderate severity HS and 11 or higher to severe disease.

    Time frame: at week 12

Secondary outcomes

  1. Change in Physician Global Assessment (PGA)

    Physician assessment describe by differents severity : from Clear (no nodule) to Very severe (more than 5 abscesses or fistulas) Score evaluated at baseline / week 6 / week 12/ week 24/ week 52

    Time frame: from baseline to week 52

  2. Change in Modified Sartorius score

    Score calculated by points from 0 (better) with differents parameters involved such as location / number / size / type of lesions Score evaluated at baseline / week 6 / week 12/ week 24/ week 52

    Time frame: from baseline to week 52

  3. Change in Hurley Score

    Score described with 3 stages from I (less severity) to III (most severe) Score evaluated at baseline / week 6 / week 12/ week 24/ week 52

    Time frame: from baseline to week 52

  4. Change in Hidradenitis Suppurativa Severity Score (IHS4) score

    Score calculated by points from \<3pts (Mild) to \> 11pts (Severe) by nb of nodules, nb of abscesses and nb of draining tunnels Score evaluated at baseline / week 6 / week 12/ week 24/ week 52

    Time frame: from baseline to week 52

  5. Change in Hidradenitis Suppurativa Clinical Response (HiSCR) score

    Global Assessment score of clear, minimal, or mild evaluated by (i) at least a 50% reduction in AN (abscess and nodule count), (ii) no increase in the number of abscesses and (iii) no increase in the number of draining fistulas from baseline Score evaluated at baseline / week 6 / week 12/ week 24/ week 52

    Time frame: from baseline to week 52

  6. Change in Dermatology Life Quality Index (DLQI) score (Patient's HS evaluation)

    Evaluated with the Dermatology Life Quality Index (DLQI) Score calculated by points from 0 to 30 following patient answers on quality of life questions Score evaluated at baseline / week 6 / week 12/ week 24/ week 52

    Time frame: from baseline to week 52

  7. Change of patient pain

    Intensity of pain evaluated with the visual analog scale (VAS) from 0 (no pain) to 10 (pain as bad as it could possible be) Score evaluated at baseline / week 6 / week 12/ week 24/ week 52

    Time frame: from baseline to week 52

  8. Microbiological bacterial Change on the worst lesion microbiome at W12

    By identification of microbiology bacterial metagenomics (by skin lesional swab sample)

    Time frame: at baseline and week 12

  9. Microbiological metagenomics Change on the worst lesion microbiome at W12

    By identification of multidrug resistant bacteria (by rectal swab sample)

    Time frame: at baseline and week 12

  10. Number of pain killers received by patients

    Number of pain killers prescribed for flares (acute worsening of one or more HS lesions)

    Time frame: from baseline to week 52

  11. Number of antibiotic treatments received by patients

    Number of antibiotic treatments prescribed for flares (acute worsening of one or more HS lesions)

    Time frame: from baseline to week 52

  12. Time without flare of HS

    Evaluated by number of flares reported or not using a patient journal

    Time frame: from baseline to week 52

  13. Change in BMI

    Calculated by combined weight and height measures

    Time frame: from baseline to week 52

  14. Abnormal biological value of Hemoglobin

    measured in g/L, compared to normal ranges

    Time frame: from baseline to week 12

  15. Abnormal biological value of white cells

    measured in units of cells / mm3 , compared to normal ranges

    Time frame: from baseline to week 12

  16. Abnormal biological value of neutrophils

    measured in units of cells / mm3 , compared to normal ranges

    Time frame: from baseline to week 12

  17. Abnormal biological value of platelet count

    measured in units of cells / mm3 , compared to normal ranges

    Time frame: from baseline to week 12

  18. Abnormal value of AST liver enzyme

    AST value \> 4 x Upper limit of normal

    Time frame: from baseline to week 12

  19. Abnormal value of ALT liver enzyme

    ALT value \> 4 x Upper limit of normal

    Time frame: from baseline to week 12

  20. Number of adverse events of all kind

    AE defined by SOC and PT according to MedDra dictonnary

    Time frame: from baseline to week 52

  21. Non complete drug administration

    Evaluated by total number of capsules not taken according to patient journal

    Time frame: from baseline to week 12

07

Study locations

1 of 4 sites recruiting
08

References and documents

Publications

  • Guet-Revillet H, Jais JP, Ungeheuer MN, Coignard-Biehler H, Duchatelet S, Delage M, Lam T, Hovnanian A, Lortholary O, Nassif X, Nassif A, Join-Lambert O. The Microbiological Landscape of Anaerobic Infections in Hidradenitis Suppurativa: A Prospective Metagenomic Study. Clin Infect Dis. 2017 Jul 15;65(2):282-291. doi: 10.1093/cid/cix285. PubMed 28379372 ↗
  • Guet-Revillet H, Coignard-Biehler H, Jais JP, Quesne G, Frapy E, Poiree S, Le Guern AS, Le Fleche-Mateos A, Hovnanian A, Consigny PH, Lortholary O, Nassif X, Nassif A, Join-Lambert O. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis. 2014 Dec;20(12):1990-8. doi: 10.3201/eid2012.140064. PubMed 25418454 ↗
  • Join-Lambert O, Coignard H, Jais JP, Guet-Revillet H, Poiree S, Fraitag S, Jullien V, Ribadeau-Dumas F, Theze J, Le Guern AS, Behillil S, Lefleche A, Berche P, Consigny PH, Lortholary O, Nassif X, Nassif A. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011 Feb;222(1):49-58. doi: 10.1159/000321716. Epub 2010 Nov 25. PubMed 21109728 ↗

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Supporting information: Clinical study report

Time frame: After publication, for 25 years

Access criteria: By publication in scientific journals and / or presented in scientific or medical meetings

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Feb 2027, 21 months after the start.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2019
First posted
Apr 20, 2023
StartActual
May 22, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 27, 2028
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05821478
Lead sponsor
Institut Pasteur
Collaborators
Centre Hospitalier Universitaire de Caen, Hôpital Necker-Enfants Malades, Ministry of Health, France, Assistance Publique Hopitaux De Marseille
Responsible party
Sponsor
First posted
Apr 20, 2023
Start date
May 22, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 27, 2028 (estimated)
Last update
Jul 9, 2025

Study contacts

Maïa Delage-Toriel, MD
Contact
maia.delage-toriel@pasteur.fr
+33 1 40 61 30 77
Aude Nassif, MD
Contact
aude.nassif@pasteur.fr
01 40 61 30 77
Maïa Delage-Toriel, MD
principal investigator · Institut Pasteur

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion